TERAPI3.: Protection of Intellectual Property rights of new therapeutic agents against amyloid transthyretin diseases: AT09 technology. (Q2866989)
Jump to navigation
Jump to search
Project Q2866989 in Portugal
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | TERAPI3.: Protection of Intellectual Property rights of new therapeutic agents against amyloid transthyretin diseases: AT09 technology. |
Project Q2866989 in Portugal |
Statements
25,000.0 Euro
0 references
50,000.0 Euro
0 references
50.0 percent
0 references
15 December 2017
0 references
14 December 2020
0 references
BSIM THERAPEUTICS, S.A.
0 references
Q2988326 (Deleted Item)
0 references
40°21'55.76"N, 8°39'29.95"W
0 references
O projeto TERAPI3 visa a proteção dos direitos de Propriedade Intelectual de uma nova classe de agentes terapêuticos contra doenças raras, nomeadamente doenças amiloides de transtirretina. Estes novos compostos são pequenas moléculas pertencentes à série química AT09 desenvolvida pela BSIM2. (Portuguese)
0 references
The TERAPI3 project aims to protect the intellectual property rights of a new class of therapeutic agents against rare diseases, namely transthyretin amyloid diseases. These new compounds are small molecules belonging to the AT09 chemical series developed by BSIM2. (English)
7 July 2021
0 references
Le projet TERAPI3 vise à protéger les droits de propriété intellectuelle d’une nouvelle classe d’agents thérapeutiques contre les maladies rares, à savoir les maladies amyloïdes de la transthyrétine. Ces nouveaux composés sont de petites molécules appartenant à la série chimique AT09 développée par BSIM2. (French)
4 December 2021
0 references
Das Projekt TERAPI3 zielt darauf ab, die Rechte des geistigen Eigentums einer neuen Klasse von therapeutischen Wirkstoffen gegen seltene Krankheiten, nämlich Transthyretin-Amyloiderkrankungen, zu schützen. Bei diesen neuen Verbindungen handelt es sich um kleine Moleküle der von BSIM2 entwickelten Chemikalie AT09. (German)
13 December 2021
0 references
Het TERAPI3-project heeft tot doel de intellectuele eigendomsrechten van een nieuwe klasse van therapeutische middelen te beschermen tegen zeldzame ziekten, namelijk transthyretine amyloïdenziekten. Deze nieuwe verbindingen zijn kleine moleculen die behoren tot de AT09 chemische serie ontwikkeld door BSIM2. (Dutch)
18 December 2021
0 references
Il progetto TERAPI3 mira a proteggere i diritti di proprietà intellettuale di una nuova classe di agenti terapeutici contro le malattie rare, vale a dire le malattie amiloidi transtiretina. Questi nuovi composti sono piccole molecole appartenenti alla serie chimica AT09 sviluppata da BSIM2. (Italian)
17 January 2022
0 references
Cantanhede
0 references
Identifiers
CENTRO-01-0247-FEDER-037867
0 references